A Randomized Double-Blind Placebo-Controlled Study to Evaluate the Efficacy and Safety of Evinacumab in Patients with Severe Hypertriglyceridemia for the Prevention of Recurrent Acute Pancreatitis

Brief description of study

The primary objective of the study is to determine the proportion of patients with elevated triglycerides (TG), without Familial Chylomicronemia Syndrome (FCS) due to loss of function (LoF) mutations in lipoprotein lipase (LPL), and a history of hypertriglyceridemia (HTG)-associated acute pancreatitis (AP) who experience a recurrent episode of AP after treatment with evinacumab versus placebo. Purpose of the Research Study is to see how safe and effective the study drug, evinacumab is when used to treat severe hypertriglyceridemia (elevated fat levels in the blood), which may increase the risk for pancreatitis (inflammation of the pancreas).

Clinical Study Identifier: s21-01062
ClinicalTrials.gov Identifier: NCT03452228

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.